Javed Butler is an expert in Cardiology at Baylor Scott & White Health (United States). As of October 2026, ScienceLeadR ranks Javed Butler in the top 1% of experts worldwide for Heart Failure, Iron Deficiencies and Iron Metabolism Disorders. Javed Butler has authored 2,021 publications, the most recent in 2026, and is an investigator in 74 clinical trials, 3 of them ongoing. SLR score: 8,428 (community average: 125). How the SLR is computed.

LeadR Profile

Javed Butler Baylor Scott & White Health United States
8 428 ScienceLeadR Reputation 8428
Network Map

Cardiology

Subspecialties: Endocrinology - Public Health - Nephrology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Short Biography

Javed Butler, MD, MPH, MBA, is the President of the Baylor Scott and White Research Institute and Senior Vice President for the Baylor Scott and White Health in Dallas, Texas. He currently holds the Maxwell A. and Gayle H. Clampitt Endowed Chair for research. He is also the Distinguished Professor of Medicine at University of Mississippi in Jackson, Mississippi. Prior to joining Baylor Scott and White Health, he served as the Patrick H. Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi, where he was also Professor of Physiology. Prior to joining the University of Mississippi, he was Charles A. Gargano Professor and Director of the Division of Cardiovascular Medicine and Co-Director of the Heart Institute at Stony Brook University, New York. He had served as the director for heart failure research at Emory University and director of the heart and heart-lung transplant programs at Vanderbilt University prior to that.


He received his medical degree from the Aga Khan University and then completed residency training at Yale University, cardiology fellowship and advanced heart failure and transplant fellowships at Vanderbilt University, and cardiac imaging fellowship at the Massachusetts General Hospital at the Harvard Medical School. He has completed Master of Public Health degree from Harvard University and Master of Business Administration from Emory University.


Dr. Butler is board certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure. He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association.


Dr. Butler has authored more than 1400 peer-reviewed publications. He serves on the editorial board of several peer reviewed cardiovascular journals. He has been cited numerous times in America’s Best Doctors list.

Organizations

Career arc: 2002 - 2026

Source: PubMed

University of Mississippi

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 2021

Citations

Citations: 132 339 1st author: 154 Last author: 464 Unique author: 8


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Anti-Inflammatory Effects of Oral NLRP3 Inhibition With Ruvonoflast Among Individuals at Elevated Cardiovascular Risk.
PMID 42187339 — cardiology, biomarkers, fibrinogen, body weight, therapeutics
J Am Coll Cardiol20261
A NETwork meta-analysis with COST-effectiveness evaluation of pharmacological treatments for heart failure with reduced ejection fraction: NET-COST-HFrEF.
PMID 42462167 — heart failure, heart, network meta-analysis, heart failure, systolic, therapeutics
Eur J Heart Fail20261
Beyond HFmrEF: New Classification, Unchanged Treatment Evidence.
PMID 42949675 — heart failure, heart failure, diastolic, classification, cardiology, therapeutics
J Am Coll Cardiol20260
Cortisol in cardio-kidney-metabolic disease.
PMID 42946534 — diabetes mellitus, hypertension, metabolic diseases, kidney, cardiology, therapeutics, hydrocortisone, cushing syndrome, diabetes mellitus, type 2
Eur Heart J Top journal20260
Redefining Cardiometabolic Disease: Expert Consensus on the CardioVascular-Kidney-Liver-Metabolic (CVKLM) Multiorgan Staging.
PMID 42945405 — liver diseases, diabetes mellitus, heart, cardiovascular diseases, kidney, liver, obesity, therapeutics
Eur J Prev Cardiol20260

Clinical Studies 74

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 8 Study Chair: 1 Study Director: 1

By phase:

Phase 3 26
N/A 24
Phase 2 12
Phase 4 7
Phase 1 3
Phase 1/Phase 2 1
Phase 2/Phase 3 1

By status:

Completed 64
Recruiting 4
Terminated 4
Active not recruiting 1
Unknown 1

By type:

Interventional 66
Observational 8

By Monocentric/Multicentric:

monocentric 10
multicentric2to4 6
multicentric5to9 7
multicentricup10 51

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR II) (IDE G210258)
NCT06898515 — heart failure, heart, diuretics, therapeutics, furosemide
N/ARecruiting2025
HeartShare Combining Omics Deep Phenotyping and Electronic Health Records for Heart Failure Subtypes and Treatment Targets
NCT05873634 — heart failure, heart, heart failure, diastolic, electronic health records, records, therapeutics
N/ARecruiting2023
Assessment of CCM in HF With Higher Ejection Fraction
NCT05064709 — quality of life, heart failure, heart, heart failure, diastolic, therapeutics, cardiac contractility modulation
N/ARecruiting2022

LeadR Networks

Main global connection map